Inventor

EISENBACH-SCHWARTZ MICHAL

IL43 patents

⚠️ This page may combine multiple inventors who share the name “EISENBACH-SCHWARTZ MICHAL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

EISENBACH-SCHWARTZ MICHAL

YEDA RES & DEV

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer&#39;s disease

Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Anti-inflammatory dipeptide and pharmaceutical composition thereof

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Use of copolymer 1 and related peptides and polypeptides and T cells treated herewith for neuroprotective glaucoma therapy

Mononuclear phagocytes and their use to promote axonal regeneration

Methods of use of mononuclear phagocytes to promote axonal regeneration

Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides

Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

Poly-Glu,Tyr for neuroprotective therapy

Use of poly-Glu,Tyr for neuroprotective therapy

Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis

Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS

Compositions of mononuclear phagocytes useful for promoting axonal regeneration

Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor

Process for the manufacturing of human mononuclear phagocytic leukocytes

Modified kisspeptin peptides and uses thereof

Vaccine and method for treatment of neurodegenerative diseases

Human monocyte sub-population for treatment of eye diseases and disorders

Human monocyte sub-population for treatment of central nervous system injury

EISENBACH-SCHWARTZ MICHAL

GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities

Vaccine and method for treatment of neurodegenerative diseases

Method of treatment of age-related macular degeneration

Eye-drop vaccine containing copolymer 1 for therapeutic immunization

IMMUNOBRAIN CHECKPOINT INC

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

NEUROQUEST LTD

Compositions, kits, and methods for detecting preclinical alzheimer&#39;s disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease

Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease

Compositions, kits, and methods for detecting preclinical alzheimer's disease